WO1993022260A1 - Radiolabelled compound formulations - Google Patents

Radiolabelled compound formulations Download PDF

Info

Publication number
WO1993022260A1
WO1993022260A1 PCT/GB1993/000869 GB9300869W WO9322260A1 WO 1993022260 A1 WO1993022260 A1 WO 1993022260A1 GB 9300869 W GB9300869 W GB 9300869W WO 9322260 A1 WO9322260 A1 WO 9322260A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
rcp
organic compound
dye
control
Prior art date
Application number
PCT/GB1993/000869
Other languages
French (fr)
Inventor
Roger Malcolm Price
Christopher Charles May
Elizabeth Margaret Buckley
Timothy Stone
Original Assignee
Amersham International Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8211352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1993022260(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amersham International Plc filed Critical Amersham International Plc
Priority to DK93911868T priority Critical patent/DK0594837T4/en
Priority to AU42665/93A priority patent/AU655548B2/en
Priority to JP05515158A priority patent/JP3117719B2/en
Priority to EP93911868A priority patent/EP0594837B2/en
Priority to CA002105402A priority patent/CA2105402C/en
Priority to DE69301300T priority patent/DE69301300T3/en
Priority to US08/107,733 priority patent/US5494654A/en
Publication of WO1993022260A1 publication Critical patent/WO1993022260A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0491Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00Purification; Separation; Stabilisation; Use of additives
    • C07B63/04Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Definitions

  • radiochemicals to experimental systems, such as protein or nucleic acid manipulation.
  • 32-P radiolabelled nucleotides are often sold as buffered aqueous solutions shipped in dry ice and sold for storage by the customer at -20oC. It would be a significant advantage, both to the shipper and to the customer, if the radiolabelled nucleotides could be supplied at ambient temperature and stored in an
  • radiolabelled organic chemical might be used.
  • the invention provides a composition
  • a composition comprising an organic compound labelled with a ⁇ -emitting radionuclide, said radiolabelled organic compound being subject to radiolytic
  • a stabiliser selected from tryptophan, paraaminobenzoate, indoleacetate, luminol, and the group of azoles which are compounds having a 5-membered ring with at least two ring nitrogen atoms directly bonded to one another.
  • the invention provides a composition comprising a solution of an organic compound
  • the invention is mainly concerned with radiolabelled organic compounds which are supplied, shipped and stored in solution, usually aqueous
  • compositions in the solid state e.g. those produced by lyophilising or otherwise drying liquid compositions.
  • the invention is applicable to radiolabelled organic compounds which are subject to radiolytic self-decomposition, for example: amino acids, steroids, lipids, fatty acids, peptides, carbohydrates, proteins, and particularly nucleotides, thionucleotides,
  • nucleosides and nucleic acids.
  • the nature of the ⁇ -emitting radionuclide is not critical; 3-H and 14-C are possible, but 32-P, 35-S and 33-P are preferred.
  • the stabiliser is preferably selected from L- and D-tryptophan; para-aminobenzoate which term is used to include the free acid and salts and esters thereof; indoleacetate which term is used to include the free acid and salts and esters thereof; luminol (3-aminophthalhydrazide); and the group of azoles which are compounds having a 5-membered ring with at least two ring nitrogen atoms directly bonded to one another. Such compounds preferably have the structure
  • Y and Z may represent N or one of X, Y and Z may represent S, the remaining X, Y and Z representing C,
  • R 5 represents -OH, -SH, -H. -COOH, -NH 2 , -CH 3 attached to the ring directly or via a chain of up to 10 carbon atoms, or two adjacent members of R 1 , R 2 , R 3 , R 4 and R 5 may together constitute an aromatic ring.
  • R 5 will or will not be present depending on the nature of X, Y and Z and on the positions of the two double bonds.
  • Examples of classes of azole compounds are azole compounds
  • the concentration of stabiliser is sufficient to reduce radiolytic decomposition of the radiolabelled organic compound, while not being so high as to materially interfere with the reaction systems where the
  • radiolabelled organic compound is to be used.
  • Preferred concentrations in liquid compositions are in the range of 1 mM to 1M, particularly 10 to 100 mM. Used in these concentrations, the preferred compounds have proved effective stabilisers particularly for nucleotides.
  • the dye is preferably selected from
  • Sulphorhodamine B Xylene Cyanol, Azocarmine B and New Coccine.
  • Other possible dyes include Orange G, Tartrazine, Safranin O, Methyl Green, Bromophenol Blue, Eosin, Evans Blue, Brilliant Blue G, Bromocresol Green, Ponceau S, Carmoisine Red, Remazol Red RB, Sandoz
  • concentration of the dye should be sufficient to visibly colour the solution, but not so high as to materially interfere with the reaction systems into which the radiolabelled organic compound is to be introduced.
  • Preferred dye concentrations are from 20 to 3000 ⁇ g/ml, particularly 50 to 400 ⁇ g/ml; that is to say approximately (depending on the
  • the dyes do have a mild stabilising effect, in addition to providing colour.
  • the colour of compositions containing these dyes does fade with time, possibly due to radiolytic rupture of double bonds of the ring structures of the dyes. While this fading does not render the
  • compositions unworkable it may nevertheless be
  • the radiolabelled organic compound composition includes both the dye and the stabiliser.
  • the stabiliser helps to prevent the dye from fading.
  • the dye improves the visibility of the radiochemical.
  • the dye and the stabiliser may act synergistically to improve the stability of the radiolabelled organic compound.
  • compositions of this invention may contain buffers.
  • the nature of the buffer is not critical to the invention, but standard commercial diluents for nucleotides consisting of an aqueous buffered solution stabilised by 2-mercaptoethanol or dithiothreitol are preferred systems. These are the systems that are used in the examples below. But other systems have been tested and shown to be equally effective.
  • Radiolabelled nucleotides and other organic compounds are conventionally shipped and stored at -20oC or below, requiring the use of dry ice.
  • compositions according to this invention are suitable for shipment and storage either at 4oC (on ice) or more preferably at ambient temperature.
  • compositions were made up and tested for stability.
  • Some of the tabulated experimental data refers to batches of dCTP labelled with 32 Phosphorus, but the stabilising compounds were also tested with the other 32 Phosphorus alpha-labelled nucleotides dATP, dGTP and dTTP.
  • Stability testing was therefore carried out for 21 days to approximate the length of customer usage.
  • test results are expressed as absolute percentage incorporation of the nucleotide compared with a control formulation, from the same batch, based on the above diluent without further added stabiliser or dye and stored at RT or +4oC or -20.C.
  • the radiochemical purity of the labelled nucleotide was measured after storage for various intervals, using thin layer chromatography plates which were subsequently scanned using a Raytek RITA scanner. This is reported as RCP.
  • Formulations were tested in various nucleic acid assays and manipulations: Sanger dideoxy sequencing using T7, Taq and Klenow DNA polymerase enzymes, random primed and nick translated DNA
  • Probes generated as above were used in genomic hybridisations for single copy
  • Biochem. 137, 266-267 (1984)) was selected as providing a stringent and representative test of radiolabelled organic compound stability and activity for the dNTPs: 5'end labelling was selected as the principal test for 32 P gamma-labelled ATP.
  • RCP refers to the radiochemical purity of the sample
  • SB, XY, AB and NC are Sulphorhodamine B,
  • pABA is para-aminobenzoate.
  • IAA is indoleacetic acid.
  • 2ME is 2-mercaptoethanol and DTT is dithiothreitol.
  • Storage conditions designated +40/RT/+4 indicate that the nucleotide was stored at +40oC for 24 hours, then at room temperature (RT; 21-24oC) for 48 hours before being stored at +4oC for the remainder of the test period.
  • Control samples consist of Amersham International's current selling nucleotide formulation, without the addition of any further stabiliser or dye.
  • the 32P labelled nucleotide (dCTP) was used at a specific activity of 3000 Ci/mmol and a concentration of 10 mCi/ml. 1 mCi lots were used for tests. Unless otherwise stated, the formulation used was an aqueous buffered diluent stabilised by 2-mercaptoethanol.
  • Formulations containing the two dyes Sulphorhodamine B and Xylene Cyanol were made up and tested under different temperature storage conditions. Both dyes are seen to have a minor stabilising effect at +4oC.
  • Formulations containing the stabiliser pABA K at the normal concentration of 50 mM and the dye New Coccine were tested.
  • the dye was used at a final molarity of 3.5 ⁇ 10 -4 mol/l (equivalent to
  • Sulphorhodamine B at 200 ⁇ g/ml). Storage was at RT, 37oC or 42-45oC for either 1, 2 or 3 days as indicated, to test the robustness of the dye. After this period, all pots were stored at +4oC for the remainder of the test period.
  • Formulations containing two different dyes and two different stabilisers were tested. Both dyes were used at a concentration of 400 ⁇ g/ml.
  • L-Tryptophan and potassium p-aminobenzoate were used at concentrations of 25 mM and 50 mM respectively.
  • a formulation containing 50 mM pABA K + was stored at RT, 37oC or 42-45oC for either 1, 2 or 3 days to test the robustness of the stabiliser.
  • Formulations containing different stabilisers were made up with and without 400 ⁇ g/ml of
  • nucleotide used in testing was 35 S dATP at a concentration of 10 mCi/ml. All the stabilising compounds were used at a
  • DTT Dithiothreitol
  • radioactive concentration of the dCTP was 10 mCi/ml. All samples contained 5 mM 2-mercaptoethanol. Storage conditions were +40/RT/+4 except for the -20oC control.
  • Formulations containing stabiliser and/or dye were tested on dATP (alpha-35S) nucleotide solutions which were at 10 mCi/ml radioactive concentration.
  • the labelling on the table shows the stabiliser and/or dye present in each sample including their respective concentrations. Storage conditions were +40/RT/+4 except for the -20oC control.
  • Stabilisers were tested on dATP (alpha 35S) nucleotide solutions. All the samples were pH 10.0 and the radioactive concentration was 10 mCi/ml. All samples contained 20 mM DTT. Storage conditions were +40/RT/+4, except for the first two controls which were stored at -20oC.
  • Stabilisers were tested on 33P gamma-labelled ATP. All samples contained 0.1% 2-mercaptoethanol. The radioactive concentration was 5 mCi/ml. All samples were stored at +4oC except the one control sample stored at -20oC, (there was no temperature cycling).
  • Stabilisers were tested on 35S labelled methionine. All samples contained 0.1% 2-mercaptoethanol. The radioactive concentration was 34 mCi/ml. All samples were stored at +4oC except the first Control sample which was stored at -20oC.
  • the stabilisers provided some stabilisation compared with the RT control sample. All samples performed well. The 14C half-life is very long (5730 years) and because of this, 14C-labelled compounds would be expected to be more stable. Long-term stability studies would be expected to show that the samples containing stabilisers have a significant stability improvement compared with controls.
  • stabilisers does not reduce the stability of L-(5-3H) Proline and (8-14C) ATP.

Abstract

Additives are proposed for compositions comprising radiolabelled organic compounds e.g. 32P-labelled nucleotides. Stabilisers are selected from tryptophan, para-aminobenzoate, indoleacetate and the azole group. Dyes are selected from Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine. Preferred compositions contain both stabiliser and dye.

Description

RADIOLABELLED COMPOUND FORMULATIONS
Radiolytic self-decomposition of
radiochemicals has always been a problem to
manufacturers and users alike. Shelf-life can be as little as a few weeks despite the use of the most suitable storage temperatures and physical dispersal methods for each particular compound or isotope. The subject is discussed in Review 16, Self-decomposition of Radiochemicals, Amersham International pic,
Amersham.
Generally applicable additives which could be added to radiochemicals in order to extend shelf-life and improve efficiency by minimising the formation of radioactive impurities, would be of great economic and scientific value. A user of a stabilised radiochemical would benefit from being able to conduct experiments over a longer time span, achieve more consistent results between batches of the same radiochemical, and use less rigorous storage conditions. The additive should minimally interfere with or be compatible with the processes occurring in the application of
radiochemicals to experimental systems, such as protein or nucleic acid manipulation.
US 4,390,517 teaches the use of a wide range of soluble primary, secondary and tertiary amines as stabilisers for radiolabelled compounds.
US 4,411,881 teaches the use of
thiocarbonylated amines as stabilisers.
US 4,451,451 teaches the use of 4-aminobenzoic acid as an -antioxidant in compositions containing Technetium-99m.
US 4,793,987 teaches the use of a range of pyridine carboxylic acids as stabilisers.
32-P radiolabelled nucleotides are often sold as buffered aqueous solutions shipped in dry ice and sold for storage by the customer at -20ºC. It would be a significant advantage, both to the shipper and to the customer, if the radiolabelled nucleotides could be supplied at ambient temperature and stored in an
unfrozen form.
Solutions of radiolabelled nucleotides and other organic compounds are generally sold colourless. A coloured solution would be an advantage, since it would make the solution more easily visible during manipulation. However, a suitable dye would need not to interfere with any process in which the
radiolabelled organic chemical might be used.
In one aspect the invention provides a composition comprising an organic compound labelled with a β-emitting radionuclide, said radiolabelled organic compound being subject to radiolytic
decomposition during storage and shipment, together with a stabiliser selected from tryptophan, paraaminobenzoate, indoleacetate, luminol, and the group of azoles which are compounds having a 5-membered ring with at least two ring nitrogen atoms directly bonded to one another.
In another aspect, the invention provides a composition comprising a solution of an organic
compound labelled with a β-emitting radionuclide and a dye.
The invention is mainly concerned with radiolabelled organic compounds which are supplied, shipped and stored in solution, usually aqueous
solution or less usually in solution in a hydrophilic organic solvent. The invention also encompasses
compositions in the solid state e.g. those produced by lyophilising or otherwise drying liquid compositions. The invention is applicable to radiolabelled organic compounds which are subject to radiolytic self-decomposition, for example: amino acids, steroids, lipids, fatty acids, peptides, carbohydrates, proteins, and particularly nucleotides, thionucleotides,
nucleosides and nucleic acids.
The nature of the β-emitting radionuclide is not critical; 3-H and 14-C are possible, but 32-P, 35-S and 33-P are preferred.
The stabiliser is preferably selected from L- and D-tryptophan; para-aminobenzoate which term is used to include the free acid and salts and esters thereof; indoleacetate which term is used to include the free acid and salts and esters thereof; luminol (3-aminophthalhydrazide); and the group of azoles which are compounds having a 5-membered ring with at least two ring nitrogen atoms directly bonded to one another. Such compounds preferably have the structure
Figure imgf000005_0001
which structure contains two ring double bonds, wherein
- one or two of X, Y and Z may represent N or one of X, Y and Z may represent S, the remaining X, Y and Z representing C,
- when present each of R1 , R2, R3, R4 and
R5, represents -OH, -SH, -H. -COOH, -NH2, -CH3 attached to the ring directly or via a chain of up to 10 carbon atoms, or two adjacent members of R1, R2, R3, R4 and R5 may together constitute an aromatic ring.
It will be understood that R 1, R2 , R3, R4 and
R5 will or will not be present depending on the nature of X, Y and Z and on the positions of the two double bonds. Examples of classes of azole compounds
envisaged are
Figure imgf000006_0001
Among the possible compounds from the azole group are those illustrated in the Examples. The concentration of stabiliser is sufficient to reduce radiolytic decomposition of the radiolabelled organic compound, while not being so high as to materially interfere with the reaction systems where the
radiolabelled organic compound is to be used.
Preferred concentrations in liquid compositions are in the range of 1 mM to 1M, particularly 10 to 100 mM. Used in these concentrations, the preferred compounds have proved effective stabilisers particularly for nucleotides.
The dye is preferably selected from
Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine. Other possible dyes include Orange G, Tartrazine, Safranin O, Methyl Green, Bromophenol Blue, Eosin, Evans Blue, Brilliant Blue G, Bromocresol Green, Ponceau S, Carmoisine Red, Remazol Red RB, Sandoz
Black, Sandoz Violet, Sandoz Brilliant Green, Remazol Golden Yellow, Remazol Red B, Acid Red 40, Acid
Alizarin Violet N, Mordant Brown 6 and BPBDTC (3,3'-(4,4'-biphenylene)-bis(2,5-diphenyl-2H-tetrazolium chloride). The concentration of the dye should be sufficient to visibly colour the solution, but not so high as to materially interfere with the reaction systems into which the radiolabelled organic compound is to be introduced. Preferred dye concentrations are from 20 to 3000 μg/ml, particularly 50 to 400 μg/ml; that is to say approximately (depending on the
molecular weight of the dye) from 3 × 10-5 to
6 × 10-3 mol/l particularly 8 × 10-5 to 1 × 10-3 mol/l. At these concentrations, the dyes do have a mild stabilising effect, in addition to providing colour. However, the colour of compositions containing these dyes does fade with time, possibly due to radiolytic rupture of double bonds of the ring structures of the dyes. While this fading does not render the
compositions unworkable, it may nevertheless be
inconvenient. The structural formulae of the preferred stabilisers and dyes used in this invention are given in Tables 1 and 2 respectively.
According to a further and preferred aspect of the invention, the radiolabelled organic compound composition includes both the dye and the stabiliser. This has several advantages. The stabiliser helps to prevent the dye from fading. The dye improves the visibility of the radiochemical. The dye and the stabiliser may act synergistically to improve the stability of the radiolabelled organic compound.
The compositions of this invention may contain buffers. The nature of the buffer is not critical to the invention, but standard commercial diluents for nucleotides consisting of an aqueous buffered solution stabilised by 2-mercaptoethanol or dithiothreitol are preferred systems. These are the systems that are used in the examples below. But other systems have been tested and shown to be equally effective.
Radiolabelled nucleotides and other organic compounds are conventionally shipped and stored at -20ºC or below, requiring the use of dry ice.
Preferred compositions according to this invention are suitable for shipment and storage either at 4ºC (on ice) or more preferably at ambient temperature. Experimental
In the examples below, various compositions were made up and tested for stability. Some of the tabulated experimental data refers to batches of dCTP labelled with 32 Phosphorus, but the stabilising compounds were also tested with the other 32 Phosphorus alpha-labelled nucleotides dATP, dGTP and dTTP.
Testing of these stabilisers was also carried out with 32 Phosphorus gamma-labelled ATP and with 35 Sulphur alpha-labelled dATP. The half-life of 32P is 14.3 days, but batches for sale are typically reference-dated for the Friday of the week following sale.
Stability testing was therefore carried out for 21 days to approximate the length of customer usage.
Stabilisation of various compounds labelled with 3H, 14C and 33P was also investigated.
All test results are expressed as absolute percentage incorporation of the nucleotide compared with a control formulation, from the same batch, based on the above diluent without further added stabiliser or dye and stored at RT or +4ºC or -20.C.
Various tests of nucleotide stability were performed :
The radiochemical purity of the labelled nucleotide was measured after storage for various intervals, using thin layer chromatography plates which were subsequently scanned using a Raytek RITA scanner. This is reported as RCP.
Formulations were tested in various nucleic acid assays and manipulations: Sanger dideoxy sequencing using T7, Taq and Klenow DNA polymerase enzymes, random primed and nick translated DNA
labelling reactions on both phage lambda and human genomic probes such as raf-1 and N-ras, and PCR
labelling of probes. Probes generated as above were used in genomic hybridisations for single copy
detection, and in colony screening. 3' end tailing and 5' end labelling of probes were also carried out, the latter specifically using the 32 Phosphorus gamma-labelled ATP.
Other techniques used were cDNA first strand synthesis and protein phosphorylation.
From these, random primed probe generation (in Amersham International Multiprime kit reactions: Amersham kit RPN 1600 based on Feinberg and Vogelstein, Anal. Biochem. 132, 6-13 (1983) and Addendum Anal.
Biochem. 137, 266-267 (1984)) was selected as providing a stringent and representative test of radiolabelled organic compound stability and activity for the dNTPs: 5'end labelling was selected as the principal test for 32 P gamma-labelled ATP.
In the following examples, RCP refers to the radiochemical purity of the sample, MP to %
incorporations obtained using the random primed DNA labelling technique in Amersham International's
Multiprime kit.
SB, XY, AB and NC are Sulphorhodamine B,
Xylene Cyanol, Azocarmine B and New Coccine respectively. pABA is para-aminobenzoate. IAA is indoleacetic acid. 2ME is 2-mercaptoethanol and DTT is dithiothreitol.
Storage conditions designated +40/RT/+4 indicate that the nucleotide was stored at +40ºC for 24 hours, then at room temperature (RT; 21-24ºC) for 48 hours before being stored at +4ºC for the remainder of the test period.
Control samples consist of Amersham International's current selling nucleotide formulation, without the addition of any further stabiliser or dye.
EXAMPLES 1 TO 8
In Examples 1-8, the 32P labelled nucleotide (dCTP) was used at a specific activity of 3000 Ci/mmol and a concentration of 10 mCi/ml. 1 mCi lots were used for tests. Unless otherwise stated, the formulation used was an aqueous buffered diluent stabilised by 2-mercaptoethanol.
Example 1
Formulations containing different
concentrations of stabilisers were tested. All
stabilisers worked well.
SAMPLE STORAGE DAY 8 DAY 15 DAY 22
RCP MP RCP MP RCP MP
CONTROL +40/RT/+4 - 1 21 - 12 0
L-TRYPTOPHAN 25 mM " 70 54 78 - 69 60 pABA Na 50 mM " 79 73 77 - 79 66 pABA K 50 mM " 80 71 82 - 79 70 IAA 50 mM " 81 74 83 - 77 64 Example 2
Formulations containing the two dyes Sulphorhodamine B and Xylene Cyanol were made up and tested under different temperature storage conditions. Both dyes are seen to have a minor stabilising effect at +4ºC.
SAMPLE STORAGE DAY 7 DAY 14 DAY 23
RCP MP RCP MP RCP MP
CONTROL -20°C 87 68 79 65 82 67
SB 400 μg/ml 87 61 81 65 84 69
XY 77 60 73 64 74 60
CONTROL +40/RT/+4 13 11 6 0 0 0
SB 400 μg/ml 35 35 15 9 0 0
XY 29 30 16 5 0 0
Example 3
Formulations containing the stabiliser pABA K at the normal concentration of 50 mM and the dye New Coccine were tested. The dye was used at a final molarity of 3.5 × 10-4 mol/l (equivalent to
Sulphorhodamine B at 200 μg/ml). Storage was at RT, 37ºC or 42-45ºC for either 1, 2 or 3 days as indicated, to test the robustness of the dye. After this period, all pots were stored at +4ºC for the remainder of the test period.
SAMPLE STORAGE WK 0 WK 1 WK 2 WK3
RCP MP RCP MP RCP MP RCP MP
CONTROL -20°C 95 88 91 82 91 91 - 73
CONTROL +40/RT/+4 89 80 94 57 95 66 - 12
NC+pABA K 72 HRS @ RT 92 75 93 71 76 76 - -
'' 24 HRS @ 37 97 72 91 82 82 83 - 74
'' 48 HRS @ 37 92 64 92 83 91 82 - 64
'' 72 HRS @ 37 79 73 94 83 94 79 - -
'' 24 HRS @ 42 89 75 94 81 90 79 - 36
'' 48 HRS @ 42 92 81 93 76 91 69 - -
'' 72 HRS @ 42 96 77 77 81 91 76 - -
Example 4
RCP's and % incorporations using the Multiprime assay were also measured for Azocarmine B, with experimental details as for Example 3. The dye was used at a final molarity of 3.5 × 10-4 mol/l.
SAMPLE STORAGE WK 0 WK 1 WK 2 WK 3
RCP MP RCP MP RCP MP RCP MP
CONTROL -20°C 93 89 88 82 93 91 - 71
CONTROL +40/RT/+4 93 88 64 58 73 39 - 4
AB+pABA K 72 HRS @ RT 91 79 89 86 81 74 - -
'' 24 HRS @ 37 91 88 93 83 89 81 - 76
'' 48 HRS @ 37 93 77 92 80 91 77 - 66
'' 72 HRS @ 37 93 81 92 73 93 69 - ¬
'' 24 HRS @ 42 94 73 93 76 91 71 - 78
'' 48 HRS @ 42 90 82 93 81 93 78 - ¬
'' 72 HRS @ 42 93 50 92 77 91 68 -
Example 5
Formulations containing two different dyes and two different stabilisers were tested. Both dyes were used at a concentration of 400 μg/ml.
L-Tryptophan and potassium p-aminobenzoate were used at concentrations of 25 mM and 50 mM respectively.
SAMPLE STORAGE DAY 8 DAY 15 DAY 21
RCP MP RCP MP RCP MP
CONTROL +40/RT/+4 12 2 6 1 3 1
SB 400 μg/ml+L Tryp " 71 48 66 49 61 34
SB 400 μg/ml+pABA K " 76 52 67 53 66 41
XY 400 μg/ml+L Tryp " 75 67 62 58 55 40
XY 400 μg/ml+pABA K " 79 66 71 67 70 61
Example 6
A formulation containing 50 mM pABA K+ was stored at RT, 37ºC or 42-45ºC for either 1, 2 or 3 days to test the robustness of the stabiliser.
All conditions except the control contain
50 mM pABA K.
After times at elevated temperatures as indicated, all conditions were stored at +4ºC for the remaining test period except for the unstabilised control, which was kept at -20ºC throughout.
SAMPLE STORAGE DAY 7 DAY 14
RCP MP RCP MP
CONTROL -20°C 89 85 86 78
pABA K 24 HRS @ RT 86 73 84 75
" 48 HRS @ RT 86 71 83 74
" 72 HRS @ RT 85 74 83 72
" 24 HRS @ 37 87 71 83 74
" 48 HRS @ 37 88 69 83 73
" 72 HRS @ 37 86 83 83 73
" 24 HRS @ 42 86 71 83 72
" 48 HRS @ 42 86 79 84 72
" 72 HRS @ 42 87 70 83 72
Example 7
Formulations containing different
concentrations of Sulphorhodamine B as dye and paraamino Benzoic acid (Potassium salt) as stabiliser, and combinations of the two in various concentrations, were tested.
SAMPLE STORAGE DAY 7 DAY 15 DAY 22
RCP MP RCP MP RCP MP
CONTROL -20°C 84 74 67 67 75 63
20mM pABA K +40/RT/+4 83 68 71 59 68 49
30 " " 84 65 79 63 74 53
40 " " 86 67 84 64 78 54
50 " " 89 69 86 70 81 62
50 μg/ml SB " 20 8 7 1 0 0
100 " " 23 10 6 1 0 0
200 " " 30 18 10 4 - 0
400 " " 37. 24 16 8 20 0
20mM pABAK//50μg/ml SB " 73 60 68 57 66 51 " 100 " " 74 62 71 57 66 52 " 200 " " 73 56 69 51 62 51 " 400 " " 78 65 77 54 67 54
30mM pABAK//50μg/ml SB " 85 68 75 64 72 56 " 100 " " 83 70 77 83 71 68 " 200 " " 77 66 71 75 70 57
" 400 " " 80 67 76 67 75 59
40mM pABAK//50μg/ml SB " 79 68 78 63 79 60 " 10 " " 84 65 78 62 77 58 " 200 " " 86 67 78 63 77 59 " 400 " " 86 67 84 65 79 63
50mM pABAK//50μg/ml SB " 88 71 87 63 83 63 " 100 " " 88 69 85 64 81 66
" 200 " " 86 72 87 63 81 68
" 400 " " 87 75 86 65 81 67 Example 8
Formulations containing different stabilisers were made up with and without 400 μg/ml of
Sulphorhodamine B.
SAMPLE STORAGE DAY 8 DAY 15 DAY 22
RCP MP RCP MP RCP MP
CONTROL +40/RT/+4 - 1 21 - 12 0
SB 400μg/ml//50mM LTRYP " 70 45 82 - 73 63 " //50mM pABANa " 79 72 88 - 78 72 " //50mM pABAK " 83 73 88 - 80 72
L TRYPTOPHAN ONLY " 70 54 78 - 69 60 pABA Na ONLY " 79 73 77 - 79 66 pABA K ONLY " 80 71 82 - 79 70
Example 9
In the following data, the nucleotide used in testing was 35S dATP at a concentration of 10 mCi/ml. All the stabilising compounds were used at a
concentration of 50 mM, and were temperature cycled at +40ºC for 24 hours and room temperature for 48 hours before long term storage at +4ºC. All samples
contained 20 mM Dithiothreitol (DTT).
SAMPLE WK 2 WK 4 WK 8 WK 14
RCP MP RCP MP RCP MP RCP MP
CONTROL -20°C 92 72 91 74 91 77 87 61
3-Amino-5-mercaptotriazole 92 67 91 73 89 78 88 53
2-Amino-1,3,4-thiadiazole 87 72 84 74 81 74 75 61
2,5-Dimercapto-1,3,4- 92 62 90 80 90 77 87 47 thiadiazole
4-Methyl-4H-1,2.4-triazole- 91 66 88 79 91 72 83 43
3-thiol
3,5-Diamino-1,2,4-triazole 91 73 84 75 83 73 65 53
3-Amino pyrazole 88 73 87 70 85 78 71 53
5-Amino-1,3,4-thiadiazole- 92 79 92 79 94 '88 71 70 2-thiol
3-Amino-5-hydroxypyτazole 84 71 84 71 83 75 72 63
1H-1 ,2,4-triazole-3-thiol 91 70 91 73 89 81 90 78
5-Mercaptotriazole 91 73 91 78 89 78 86 55
(Na+) 2H2O
p-Amino benzoic acid (K+) 79 60 81 69 66 66 58 40
5-Mercapto-1-tetrazole 91 75 86 80 78 70 53 40 acetic acid (Na+)
5-Mercapto-1-methyl 89 73 84 65 78 70 65 37 tetrazole
Stabilisation was observed in all formulations. Example 1 0
The stabilisers of Example 9 were also tested on 32P dCTP labelled nucleotide where they were again used at a working concentration of 50 mM. The
radioactive concentration of the dCTP was 10 mCi/ml. All samples contained 5 mM 2-mercaptoethanol. Storage conditions were +40/RT/+4 except for the -20ºC control.
SAMPLE DAY 6 DAY 14 DAY 21
RCP MP RCP MP RCP MP
CONTROL -20ºC 79 71 80 68 79 70 3-Amino-5-mercaptotriazole 77 70 76 68 76 66 pABA K+ 78 65 76 63 71 61
2-Amino-1,3,4-thiadiazole 73 60 65 58 68 51
2,5-Dimercapto-1,3,4-thiadiazole 79 74 78 67 79 65
4-Methyl-4H-1,2,4-triazole-3-thiol 78 75 78 77 79 69
3,5-Diamino-1,2,4-triazole 78 72 76 73 74 65 5-Mercapto-1-tetrazole 81 69 73 68 73 65 acetic acid (Na+)
5-Mercapto-1-methyl tetrazole 75 70 77 66 71 70 3-Amino pyrazole 76 73 76 65 74 63 5-Amino-1,3,4-thiadiazole-2-thiol 72 83 78 70 74 66 3-Amino-5-hydroxypyrazole 69 76 74 64 68 58 1H-1,2,4-triazole-3-thiol 76 72 78 72 78 64 5-Mercaptotriazole (Na+) 2H2O 75 71 78 68 76 67
The results indicate that these compounds showed stabilising activity of nucleotides in solution. Example 1 1
Further compounds were also tested on the 32P labelled dCTP nucleotides as for Example 10, and were again used at a working concentration of 50 mM (except for luminol which was used at a working concentration of 45 mM).
SAMPLE DAY 8 DAY 16 DAY 23
RCP MP RCP MP RCP MP
CONTROL -20°C 90 50 88 52 83 49 pABA K+ 87 44 82 33 78 31
5-Methyl-1H-benzotriazole 80 40 71 39 67 48 3-Amino-4-pyrazole carboxylic acid 84 45 81 422 75 47 3-Amino-5-mercaptotriazole 87 41 88 40 82 47 Luminol 80 39 80 44 77 47
Example 1 2
Formulations containing stabiliser and/or dye were tested on dATP (alpha-35S) nucleotide solutions which were at 10 mCi/ml radioactive concentration. The labelling on the table shows the stabiliser and/or dye present in each sample including their respective concentrations. Storage conditions were +40/RT/+4 except for the -20ºC control. SAMPLE WK 2 WK 4 WK 8 WK 14
RCP MP RCP MP RCP MP RCP MP
CONTROL -20°C 82 64 65 41 22 23 15 16
CONTROL +40/RT/+4 56 45 0 0 0 0 0 0
20 mM DTT 92 71 91 52 78 43 65 50
50 mM pABA (Na+) 88 77 77 43 76 44 54 45
25 mM Tryptophan 86 70 78 50 59 34 41 38
200 μg/ml SB 64 56 17 7 0 0 0 0
50 mM pABA, 200 μg/ml SB 86 69 74 31 67 34 48 42
DTT, pABA, SB 91 67 88 37 86 49 79 49
20 mM, 50 mM, 200 μg/ml
These results show that DTT, pABA, Tryptophan and to a small extent SB, all stabilised the 35S labelled nucleotide. The possibility of dye and stabiliser combinations was demonstrated. Example 13
Formulations containing stabilisers were tested on dATP (alpha-35S). All samples were pH 10.0. Radioactive concentration was 10 mCi/ml. The
stabilisers present are indicated in the results table for each sample. Storage conditions were +40/RT/+4. AMT = 3-Amino-5-mercaptotriazole.
SAMPLE WK 2 WK 4 WK 8 WK 14
RCP MP RCP MP RCP MP RCP MP
20 mM DTT CONTROL -20°C 94 55 89 70 81 66 78 67 50 mM AMT 95 68 94 76 90 60 88 84 50 mM AMT, 50 mM DTT 93 52 94 73 92 62 91 83 50 mM AMT, 20 mM DTT 93 64 94 84 92 70 91 84 50 mM AMT, 100 mM 2ME 95 60 94 78 92 72 93 80 50 mM AMT, 40 mM 2ME 94 50 93 73 92 70 90 77 25 mM AMT 93 67 92 81 87 70 80 69 25 mM AMT, 50 mM DTT 96 44 94 78 92 68 90 77 25 mM AMT, 20 mM DTT 96 53 93 85 90 75 89 75 25 mM AMT, 100 mM 2ME 95 45 94 72 92 76 92 83 25 mM AMT, 40 mM 2ME 95 50 92 87 91 77 89 80
It can be deduced that the three stabilisers azole, DTT and 2-ME may be used in combination to achieve adequate stabilisation. Azole stabiliser may also be used with no other stabiliser present. EXAMPLES 14 TO 21
Examples 14 to 21 show further testing of stabilisers on various radiolabelled compounds. Unless otherwise indicated, all stabilisers were used at a working concentration of 50 mM.
Example 14
Stabilisers were tested on dATP (alpha 35S) nucleotide solutions. All the samples were pH 10.0 and the radioactive concentration was 10 mCi/ml. All samples contained 20 mM DTT. Storage conditions were +40/RT/+4, except for the first two controls which were stored at -20ºC.
SAMPLE WK 2 WK 4 WK 8 WK 14
RCP MP RCP MP RCP MP RCP MP
CONTROL -20°C 95 61 92 76 90 82 90 76
CONTROL -20°C 93 51 91 78 87 80 87 76
CONTROL +40/RT/+4 92 53 58 56 40 39 30 38
5-Amino-1,3,4-thiadiazole- 95 55 91 72 90 71 85 76 2-thiol
2-Amino-1,3,4-thiadiazole 92 56 88 71 85 71 85 72
4-Methyl-4H-1,2,4- 91 49 88 63 87 64 91 68 triazole-3-thiol
3-Amino pyrazole 93 56 85 70 85 71 88 79
3,5-Diamino triazole 91 53 79 69 85 73 85 79 Example 1 5
A further experiment was carried out to test stabilisers on dATP (Alpha 35S). Experimental details were as for Example 14.
SAMPLE WK 2 WK 4 WK 8 WK 14
RCP MP RCP MP RCP MP RCP MP
CONTROL -20°C 93 67 90 74 88 72 89 76
CONTROL -20°C 93 65 90 76 87 77 84 74
CONTROL +40/RT/+4 90 61 83 77 75 71 62 60
5-Amino-1,3,4-thiadiazole- 93 54 90 79 87 66 90 76
2-thiol
4-Methyl-4H-1,2,4- 93 48 91 73 88 61 88 74 triazole-3-thiol
3-Amino pyrazole 91 64 87 78 83 70 80 80
3-Amino pyrazole- 91 61 86. 82 83 72 79 80 4-carboxylic acid
3,5-Diamino triazole 90 58 90 77 84 77 82 75
25 mM Tryptophan 90 51 90 74 ╌ 70 79 74
3-Amino-5-mercapto triazole 92 55 91 73 85 74 88 73
Example 1 6
Stabilisers were tested on 33P gamma-labelled ATP. All samples contained 0.1% 2-mercaptoethanol. The radioactive concentration was 5 mCi/ml. All samples were stored at +4ºC except the one control sample stored at -20ºC, (there was no temperature cycling).
SAMPLE DAY 6 DAY 14 DAY 45
RCP RCP RCP
CONTROL -20°C 88 86 83
CONTROL +4°C 76 64 50
5-Amino-1,3,4-thiadiazole- 90 89 87 2-thiol
4-Methyl-4H-1,2,4-triazole- 90 87 86 3-thiol
3-Amino-5-hydroxypyrazole 89 81 78
3-Amino-5-mercaptotriazole 88 77 75
3,5-Diamino-1,2,4-triazole 89 88 81
All stabilisers showed a stabilisation effect, with all the purities being greater than those of the +4'C Control. The presence of some of the stabilisers maintained the purity of the nucleotide solution more effectively than storage at -20ºC. Example 17
Stabilisers were tested on 35S labelled methionine. All samples contained 0.1% 2-mercaptoethanol. The radioactive concentration was 34 mCi/ml. All samples were stored at +4ºC except the first Control sample which was stored at -20ºC.
SAMPLE DAY 7 DAY 14 DAY 25 DAY 32
RCP RCP RCP RCP
CONTROL -20°C 84 63 41 27
CONTROL +4°C 52 10 3 ╌
5-Amino-1,3,4-thiadiazole- 95 93 87 83 2-thiol
4-Methyl-4H-1,2,4-triazole- 93 90 84 84 3-thiol
3-Amino-5-hydroxypyrazole 67 19 2 ╌
3-Amino-5-mercaptotriazole 94 94 92 92
3,5-Diamino-1,2,4-triazole 82 39 12 5
All stabilisers provided some stabilisation compared with the 4ºC control. Several of these stabilisers conferred better stability on the 35S methionine at +4ºC than storage at -20ºC without the stabilisers present. Example 18
Stabilisers were tested on 3H labelled phenylalanine. The radioactive concentration was 0.5 mCi/ml. All samples were stored at room
temperature except the first Control sample which was stored at +2ºC.
SAMPLE DAY 13 DAY 23 DAY 36 DAY 41
RCP RCP RCP RCP
CONTROL +2°C 82 74 74 68
CONTROL RT 81 71 69 62
5-Amino-1,3,4-thiadiazole- 92 90 93 92 2-thiol
3,5-Diamino-1,2,4-triazole 91 87 87 86
3-Amino-5-hydroxypyrazole 92 88 93 92
Para-aminobenzoic acid 92 88 93 91
All stabilisers provided stabilisation compared with both control samples. Excellent
stability was achieved even though storage was at room temperature.
Example 1 9
Stabilisers were tested on (Methyl-3H)
Thymidine. The radioactive concentration was
0.5 mCi/ml. All samples were stored at room
temperature except the first Control sample which was stored at +2ºC.
SAMPLE DAY 13 DAY 23 DAY 36 DAY 41
RCP RCP RCP RCP
CONTROL +2°C ╌ 74 69 68
CONTROL RT 78 73 66 64
5-Amino-1,3,4-thiadiazole- 86 87 85 85 2-thiol
3,5-Diamino-1,2,4-triazole 85 84 84 85
3-Amino-5-hydroxypyrazole 86 83 85 86
Para-aminobenzoic acid 85 86 85 86
All stabilisers provided some stabilisation compared with both control samples. Excellent
stability was achieved even though all stabilised samples were stored at room temperature.
Example 20
Stabilisers were tested on L-(U-14C)
Histidine. The radioactive concentration was
100 mCi/ml. All samples were stored at room
temperature except the first Control sample which was stored at +2ºC.
SAMPLE DAY 13 DAY 23 DAY 36 DAY 41
CP RCP RCP RCP
CONTROL +2°C 99 99 98 99 CONTROL RT 97 97 96 95
5-Amino-1,3,4-thiadiazole- 97 98 99 97 2-thiol
3,5-Diamino-1,2,4-triazole 98 97 98 98 Para-aminobenzoic acid 99 98 98 97
The stabilisers provided some stabilisation compared with the RT control sample. All samples performed well. The 14C half-life is very long (5730 years) and because of this, 14C-labelled compounds would be expected to be more stable. Long-term stability studies would be expected to show that the samples containing stabilisers have a significant stability improvement compared with controls. Example 21
The stability of other compounds was determined in a similar manner. L-(5-3H) Proline (at 0.5 mCi/ml) and (8-14C) ATP (at 0.75 mCi/ml) were analysed over a period of six weeks. It was found that these compounds were quite stable, even with no
stabiliser present. Both compounds maintained their purities at approximately 97-98%. From these results it can be concluded that the presence of the
stabilisers does not reduce the stability of L-(5-3H) Proline and (8-14C) ATP.
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001

Claims

1. A composition comprising an organic compound labelled with a β-emitting radionuclide, said
radiolabelled organic compound being subject to
radiolytic decomposition during storage and shipment, together with a stabiliser selected from tryptophan, para-aminobenzoate, indoleacetate, luminol, and the group of azoles which are compounds having a 5-membered ring with at least two ring nitrogen atoms directly bonded to one another.
2. A composition comprising a solution of an organic compound labelled with a β-emitting
radionuclide and a dye.
3. A composition comprising a radiolabelled organic compound labelled with a β-emitting
radionuclide, a dye, and a stabiliser selected from L-tryptophan, para-aminobenzoate, indoleacetate, luminol, and the group of azoles which are compounds having a 5-membered ring with at least two ring nitrogen atoms directly bonded to one another.
4. A composition as claimed in claim 1 or claim 3, wherein the radiolabelled organic compound is present in solution.
5. A composition as claimed in any one of claims 1 to 4, wherein the radiolabelled organic compound is a nucleotide.
6. A composition as claimed in any one of claims 1 to 4, wherein the radiolabelled organic compound is an amino acid.
7. A composition as claimed in any one of claims 1 to 6, wherein the radiolabel is selected from 32-P,
35-S, 33-P, 3-H and 14-C.
8. A composition as claimed in any one of claims 1 and 3 to 7, wherein the stabiliser is present at a concentration of 10 - 100 mM.
9. A composition as claimed in any one of claims 2 to 7, wherein the dye is present at a concentration of 50 - 400 μg/ml.
10. A composition as claimed in any one of claims
1 to 9, which is suitable for shipment and storage at 4ºC or ambient temperature.
11. A composition as claimed in any one of claims
2 to 10, wherein the dye is selected from
Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine.
12. A composition as claimed in any one of claims 1 to 11, wherein the azole is one having the formula
Figure imgf000036_0001
which structure contains two ring double bonds, wherein
- one or two of X, Y and Z may represent N or one of X, Y and Z may represent S, the remaining X,
Y and Z representing C,
- when present each of R1 , R2, R3, R4 and R5, represents -OH, -SH, -H, -COOH, -NH2, -CH3 attached to the ring directly or via a chain of up to 10 carbon atoms, or two adjacent members of R1 , R2, R3, R4 and R5 may together constitute an aromatic ring.
PCT/GB1993/000869 1992-04-30 1993-04-27 Radiolabelled compound formulations WO1993022260A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK93911868T DK0594837T4 (en) 1992-04-30 1993-04-27 Radiolabelled compound preparations
AU42665/93A AU655548B2 (en) 1992-04-30 1993-04-27 Radiolabelled compound formulations
JP05515158A JP3117719B2 (en) 1992-04-30 1993-04-27 Formulation of radiolabeled compounds
EP93911868A EP0594837B2 (en) 1992-04-30 1993-04-27 Radiolabelled compound formulations
CA002105402A CA2105402C (en) 1992-04-30 1993-04-27 Radiolabelled compound formulations
DE69301300T DE69301300T3 (en) 1992-04-30 1993-04-27 FORMULATIONS OF RADIO-MARKED CONNECTIONS
US08/107,733 US5494654A (en) 1992-04-30 1993-04-27 Radiolabelled compound formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92303905 1992-04-30
EP92303905.1 1992-04-30

Publications (1)

Publication Number Publication Date
WO1993022260A1 true WO1993022260A1 (en) 1993-11-11

Family

ID=8211352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/000869 WO1993022260A1 (en) 1992-04-30 1993-04-27 Radiolabelled compound formulations

Country Status (10)

Country Link
US (1) US5494654A (en)
EP (1) EP0594837B2 (en)
JP (1) JP3117719B2 (en)
AT (1) ATE132842T1 (en)
AU (1) AU655548B2 (en)
CA (1) CA2105402C (en)
DE (1) DE69301300T3 (en)
DK (1) DK0594837T4 (en)
ES (1) ES2081717T5 (en)
WO (1) WO1993022260A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727687A1 (en) * 1994-12-02 1996-06-07 Isotopchim Sarl Stabilisation of radioactively marked organic cpds.
WO1997001520A1 (en) * 1995-06-28 1997-01-16 E.I. Du Pont De Nemours And Company Composition and method for stabilizing radiolabeled organic compounds
WO1998055154A1 (en) * 1997-06-03 1998-12-10 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686058A (en) * 1992-04-30 1997-11-11 Amersham International Plc Radiolabelled nucleotide formulations stored in an unfrozen state
HU225723B1 (en) * 2001-03-21 2007-07-30 Izotop Intezet Kft Method for covering of plastic material
HUP0101921A2 (en) * 2001-05-10 2004-01-28 Izotóp Intézet Kft Radiolabelled nucleotid containing preparations and process for producing thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390517A (en) * 1979-12-19 1983-06-28 New England Nuclear Corporation Method, composition and kit for stabilizing radiolabeled compounds
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
US4451451A (en) * 1981-10-30 1984-05-29 Amersham International Plc Radiopharmaceutical composition based on technetium-99m and reagent for making it
US4793987A (en) * 1985-04-26 1988-12-27 Amersham International Plc Stabilized radiolabelled compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3261747A (en) * 1964-05-08 1966-07-19 Spencer L Commerford Stabilized iodine labeled 2'-deoxy-5-iodouridine
US3673410A (en) * 1969-06-25 1972-06-27 John H Waite Method of examination of cell samples using a radioactively tagged dye
US4095950A (en) * 1976-06-11 1978-06-20 Bio-Dynamics, Inc. Method for the chromatographic analysis of a technetium-containing mixture
JPS59125062A (en) * 1982-12-29 1984-07-19 Toshiba Corp Column type immunoanalysis method
JPS6132291A (en) * 1984-07-24 1986-02-14 Sony Corp Memory device
US4966854A (en) * 1986-02-12 1990-10-30 Linus Pauling Institute Of Science And Medicine Radio labelled dye composition for detecting proteins in gels
US5101020A (en) * 1986-02-12 1992-03-31 Linus Pauling Institute Of Science And Medicine Novel radio labeled dyes for detecting proteins in gels
JPS63118661A (en) * 1986-11-07 1988-05-23 Hitachi Ltd Nucleic acid base sequence determination instrument
JPH0235100U (en) * 1988-08-30 1990-03-06
US4880615A (en) * 1988-11-25 1989-11-14 Merck & Co., Inc. Stabilized radiopharmaceutical compositions
US5262175A (en) * 1989-05-10 1993-11-16 Solanki Kishor K Stabilization of radiopharmaceutical compositions
US5093105A (en) * 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390517A (en) * 1979-12-19 1983-06-28 New England Nuclear Corporation Method, composition and kit for stabilizing radiolabeled compounds
US4451451A (en) * 1981-10-30 1984-05-29 Amersham International Plc Radiopharmaceutical composition based on technetium-99m and reagent for making it
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
US4793987A (en) * 1985-04-26 1988-12-27 Amersham International Plc Stabilized radiolabelled compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 111, no. 11, 11 September 1989, Columbus, Ohio, US; abstract no. 93463b, K. NAGAI 'APPARATUS FOR BASE SEQUENCE DETERMINATION IN NUCLEIC ACIDS' page 388 ;column 1 ; *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727687A1 (en) * 1994-12-02 1996-06-07 Isotopchim Sarl Stabilisation of radioactively marked organic cpds.
WO1997001520A1 (en) * 1995-06-28 1997-01-16 E.I. Du Pont De Nemours And Company Composition and method for stabilizing radiolabeled organic compounds
US5738836A (en) * 1995-06-28 1998-04-14 E. I. Du Pont De Nemours And Company Composition for stabilizing radiolabeled organic compounds
US5843396A (en) * 1995-06-28 1998-12-01 Nen Life Science Products, Inc. Method for stabilizing radiolabeled organic compounds by adding a separate stabilizing compound
WO1998055154A1 (en) * 1997-06-03 1998-12-10 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US6338835B1 (en) 1997-06-03 2002-01-15 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope

Also Published As

Publication number Publication date
EP0594837B1 (en) 1996-01-10
DE69301300D1 (en) 1996-02-22
AU655548B2 (en) 1994-12-22
JP3117719B2 (en) 2000-12-18
US5494654A (en) 1996-02-27
DE69301300T3 (en) 2000-07-27
JPH06502729A (en) 1994-03-24
AU4266593A (en) 1993-11-29
CA2105402A1 (en) 1993-10-31
DK0594837T4 (en) 2000-03-27
EP0594837A1 (en) 1994-05-04
DE69301300T2 (en) 1996-05-23
ATE132842T1 (en) 1996-01-15
DK0594837T3 (en) 1996-04-09
EP0594837B2 (en) 1999-12-08
CA2105402C (en) 2000-04-04
ES2081717T5 (en) 2000-02-16
ES2081717T3 (en) 1996-03-16

Similar Documents

Publication Publication Date Title
US4668503A (en) Process for labeling amines with 99m Tc
WO1991007375A1 (en) Peracetic acid composition
US6132698A (en) Radiolabelled compound formulations containing a dye
EP0594837B2 (en) Radiolabelled compound formulations
Evans et al. Copper-free click—a promising tool for pre-targeted PET imaging
CN102712603B (en) Radioiodination method
US4880615A (en) Stabilized radiopharmaceutical compositions
EP0031121A1 (en) Method, composition and kit for stabilizing radiolabeled compounds
JPH04503059A (en) Reagents for producing 5'-biotinylated oligonucleotides
JPH0211105B2 (en)
US4793987A (en) Stabilized radiolabelled compounds
Gilissen et al. Synthesis of N‐(2‐[18F] fluoroethyl)‐N′‐methylthiourea: a hydrogen peroxide scavenger
JPH0445107B2 (en)
US6015544A (en) Process for producing radiolabelled benzodiazepine receptor agents and composition containing the same
EP0804446B1 (en) Method and composition for stabilization of labelled nucleoside triphosphates
EP4056546A1 (en) Aliphatic 18f-radiolabeling of a tetrazine precursor
Iida et al. 18F‐Fluorination of 2‐Methyl‐6‐nitrobenzenesulfonate Ester and its Application for the Synthesis of an 18F‐Labeled Amino Acid
RU2104035C1 (en) Preparation containing organic substance labeled with $$$-radionuclide
WO2005079863A1 (en) Contrast medium for thrombus formation
Conway et al. PET studies of potential chemotherapeutic agents—X. Synthesis of “no-carrier-added”(11C)-HECNU: The hydroxyethyl analog of the chemotherapeutic agent BCNU
AU654663B2 (en) Method for preparing a metal-radionuclide-labelled protein
US5294736A (en) L-buthionine-S-sulfoximine and methods of making
Kothari et al. Synthesis of 99mTc (CO) 3‐mebrofenin via [99mTc (OH2) 3 (CO) 3]+ precursor and comparative pharmacokinetics studies with 99mTc‐mebrofenin
WO2022189304A2 (en) Aliphatic 18f-radiolabeling of a tetrazine precursor
Homma et al. Brain uptake of halogenated products of D-glucal

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1993911868

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08107733

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2105402

Country of ref document: CA

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1993911868

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993911868

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1996 666834

Country of ref document: US

Date of ref document: 19960619

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 872059

Country of ref document: US

Date of ref document: 19970610

Kind code of ref document: A